Aptevo Therapeutics Reports $6.5 Million Q3 Loss and $8.3 Million in Cash
Aptevo Therapeutics reported a third-quarter 2026 net loss of $6.5 million and cash and cash equivalents of $8.3 million as of September 30. The company also highlighted clinical progress for mipletamig, including remission results in patients with high-risk TP53-mutated AML. Its August financing g…